ACTIVIN AND CANCER

Roles and mechanisms of action of activin in skin cancer

Coordinatore	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH    more  Organization address address: Raemistrasse 101 city: ZUERICH postcode: 8092 contact info Titolo: Prof. Nome: Sabine Cognome: Werner Email: send email Telefono: +41-44-633 39 41 Fax: +41-44-633 11 74
Nazionalità Coordinatore	Switzerland [CH]
Totale costo	181˙368 €
EC contributo	181˙368 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-09-01   -   2012-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH  Organization address address: Raemistrasse 101 city: ZUERICH postcode: 8092 contact info Titolo: Prof. Nome: Sabine Cognome: Werner Email: send email Telefono: +41-44-633 39 41 Fax: +41-44-633 11 74	CH (ZUERICH)	coordinator	181˙368.45

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The increase in skin cancer incidence in the past years has made the search for new therapeutic approaches to prevent or cure these malignancies a major research challenge. Importantly, the development of new therapies depends on a thorough understanding of the molecular mechanisms underlying the pathogenesis of these threatening disorders. The growth and differentiation factor activin A regulates a variety of processes, among them cutaneous homeostasis and repair. Most interestingly, recent results from the host laboratory revealed a pro-tumourigenic role of activin A in a mouse model of chemically-induced skin carcinogenesis, which is exerted via stromal cells, most likely the mast cells. The goal of the proposed project is to investigate the mechanisms underlying this pro-tumourigenic function of activin A. First, the contribution of mast cells to this effect will be determined. For this purpose mast cells will be depleted in activin A-overexpressing mice using a genetic approach, and the mice will be subjected to a chemical skin carcinogenesis protocol. In parallel, other stromal cell type(s), by which activin A might exert its pro-tumourigenic effect, will be identified. Moreover, the role of activin A in other tumour models will be determined by breeding the activin A-overexpressing mice to transgenic mice that develop papillomas without any physical or chemical treatment and to mice susceptible to malignant melanoma development. The study will be complemented by analysis of activin expression in human skin cancer biopsies. This analysis will allow us to define the roles and mechanisms of action of activin in the development of cutaneous tumours and may provide information on the potential use of activin antagonists or inhibitors of activin receptor signaling for the treatment of skin cancer. Knowledge gained from this study will thus not only be important for basic research, but will also be relevant for clinical practice.'